Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
2021 · EClinicalMedicine · 36 citations
https://doi.org/10.1016/j.eclinm.2021.101086
C
Carmen Mestre‐Durán
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
26
Papers
274
Citations
9
h-index
9
i10-index
Carmen Mestre‐Durán is an academic researcher from Hospital La Paz Institute for Health Research. The author has contributed to research in topics: Immune Cell Function and Interaction & CAR-T cell therapy research & SARS-CoV-2 and COVID-19 Research. The author has an h-index of 9, co-authored 23 publications.
ORCID: 0000-0003-3569-2345Papers by this author
worksOptimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
2021 · Cancers · 30 citations
https://doi.org/10.3390/cancers13030577
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia
2021 · Clinical Lymphoma Myeloma & Leukemia · 18 citations
https://doi.org/10.1016/j.clml.2021.01.013
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14161995
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat